Focusing on specific regions of tumors in patients with lung cancer — the leading cause of cancer death worldwide — Dr. Ralph DeBerardinis and his team at CRI analyzed the process by which different areas of tumors regulate the sources of energy needed for growth, and the manner in which the surrounding cellular environment influences that metabolic activity. The findings, published in Cell, may pave the way for exploiting cancer metabolism to predict disease progression and treat cancer.
“One of the compelling ideas cancer biologists have pursued for many years is that it might be possible to treat all cancers in a similar way by cutting off the fuel supply to the tumor cells — essentially starving them to death,” said Dr. DeBerardinis, Associate Professor of CRI and Pediatrics, Director of CRI’s Genetic and Metabolic Disease Program, and Chief of the Division of Pediatric Genetics and Metabolism at UT Southwestern. “But we were surprised in our study to find how much metabolic variety there was among the tumors — in some cases detecting different metabolic activities even within different areas of the same tumor — which makes it unlikely that a “starvation bullet” to treat cancers can be developed.”
The study also provides insight into a long-standing misconception about cancer metabolism. For nearly a century, researchers had relied upon the idea that a metabolic switch takes place when a benign tumor becomes cancerous, whereby oxidative metabolism is turned off and glycolytic metabolism is turned on. The CRI study found that there is no switch from one source of energy to the other; instead, both types of metabolism increase when a benign tissue becomes cancerous.
The study also suggests that glucose is not the sole nutrient that solid tumors consume for energy, but is one of many nutrients, a finding that potentially expands the number of metabolic pathways that could be targeted to fight a tumor’s progression.
In addition, it appears that the metabolic preference of tumors that is determined by their genetics can be overridden by the cellular environment. Tumors — and even different regions of the same tumor — that receive a lot of blood flow were found to use many different nutrients for energy. Tumors and different areas of the same tumor that receive less blood flow were more likely to use glucose as the primary fuel.
“Now that we have a much better handle on how metabolism operates in lung tumors, and where particular metabolic activities are located within a tumor, it should be easier to study exactly which activities predict and stimulate disease progression,” said Dr. DeBerardinis, who at UT Southwestern is also affiliated with the Eugene McDermott Center for Human Growth Development, holds the Joel B. Steinberg, M.D. Chair in Pediatrics, and is a Sowell Family Scholar in Medical Research.
To determine how differences in blood flow might affect tumor metabolism, the CRI research team measured the amount of blood flowing into various parts of tumors in patients by using a suite of advanced imaging techniques in collaboration with Dr. Robert Lenkinski, Professor of Radiology at UT Southwestern. The CRI team also worked with Dr. Kemp Kernstine, Professor and Chief of the Division of Thoracic Surgery at UT Southwestern, to pinpoint which regions of the tumors needed to be sampled during the removal process based on the results of the imaging investigation. Following surgical removal of the tumors, the research team performed fragment-by-fragment metabolic flux analysis to examine the metabolic changes that occurred, in collaboration with Dr. Craig Malloy, Professor and Director of the Advanced Imaging Research Center at UT Southwestern.
At UT Southwestern, Dr. Lenkinski holds the Charles A. and Elizabeth Ann Sanders Chair in Translational Research, and the Jan Bob Pickens Distinguished Professorship in Medical Science, in Memory of Jerry Knight Rymer and Annette Brannon Rymer, and Mr. and Mrs. W.L. Pickens; Dr. Kernstine holds the Robert Tucker Hayes Foundation Distinguished Chair in Cardiothoracic Surgery; and Dr. Malloy holds the Richard A. Lange, M.D. Chair in Cardiology.
“This information will provide new opportunities to identify prognostic information and, potentially, new treatment modalities for lung cancer,” said Dr. Kernstine.